Preclinical and Phase I Solutions for Early-Stage Therapeutics
OUR MISSION
Seamless CRO Precision
Rubix LS is a precision-driven CRO.
​
We have dual expertise in preclinical drug discovery and complete execution of Phase I trials.
​
Our partners enjoy the unique combination. Their research translates into marketable, tangible outcomes for all patients.
Beyond traditional CRO
Why we do it
​
To reveal broader efficiencies and make sure your drug works for the largest patient population.
​​
What you get
​
-
A complete CRO service that hit unique patient needs
-
Inclusive Design with representative disease models and research methods
-
Targeted Recruitment that reports efficiency across all populations
​
How we do it
​
-
Couple our assets with our interests in specific therapeutic assets
-
Run pre-clinical studies and clinical trials
-
Enhance RWE that expands commercialization potential
​
Deliver therapies to patients who need them the most. Work with healthcare providers to ensure that research is accessible. Inclusivity is the basis of our targeted recruitment and data.
Spot the trends that can advance your medical research. Use Rubix LS's cutting-edge data analytics to bring accurate and actionable insight.
Agencies that partner with Rubix LS secure cultural relevance, precision metrics, and timely outcomes. Deliver culturally competent research tailored to the national community's unique needs.
Rubix LS In Numbers
100+
RESEARCH STUDIES
18+
CLINICAL TRIALS LAUNCHED
50+
MEDICAL EXPERTS
20+
PARTNERSHIPS
OUR PARTNERS
We Partner with Leading Medical Institutions
Rubix LS works with a range of partners to advance medical research and improve patient outcomes. Our partners include hospitals, universities, and other medical research organizations.
HOSPITALS
UNIVERSITIES
RESEARCH ORGANIZATIONS
PHARMA/BIOTECH/LIFE-SCIENCE